ADORA2A and metabolic syndrome: From the available literature it is known that caffeine—non-selective adenosine A2A receptor antagonist is able to inhibit various obesity-related abnormalities, including low metabolism, adiposity, dyslipidemia, systemic/tissue inflammation, and insulin resistance [52].